Targeted Oncology Therapeutics – Breast Cancers


  TARGETED ONCOLOGY THERAPEUTICS – BREAST CANCERS  

 TBC201K October 2021 • US$3,850 


 

The almost two thousand active oncology clinical trials paint a picture of an evolving therapeutic sector that has established players moving quickly to realize the expanded benefits of recent treatment protocols. A dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. There approaches have attracted a growing number of drug developers anxious to profit from therapies that can ease the physical, psychological and emotional burden of breast cancers. This report examines the fifty therapeutic drugs and the biomarkers they utilize.

 

Targeted Oncology Therapeutics

 

 

 

 
 
 
 
 
 
 
 
 

What You Will Learn

• What is the market share of approved therapeutics?
• What is the global supply picture for targeted therapeutics?
• Who are the market leaders, by Indication? by Product?
• What is the therapeutic coverage across all oncology indications? What are the product opportunities?
• What are the established products in this space? by target, indication, API class, revenue?
• What is the competitive picture for the major Oncology market segments?
• Drug treatment resources
• Competitive therapy map
• Clinical trial activity
• Who are the leading competitors in the field of next-generation therapeutics?

 

Summary of Contents

Executive Summary

The Recombinant Drug Ecosystem


Biological Drug Activity by Region


Biological Oncology Market Leaders


Oncology mAbs: Competitive Considerations


mAbs and Targeted Oncology Therapeutics


Historical Growth of Biologicals


Leading Biological Drug Companies – Activity by Drug & Segment


FDA Approved mAbs Indicated for Oncology (Ado to Bre)


FDA Approved mAbs Indicated for Oncology (Cem to Ipl)


FDA Approved mAbs Indicated for Oncology (Mog to Pol


FDA Approved mAbs Indicated for Oncology (Ram to Tra)


Drugs Indicated for Specific Breast Cancers


Targeting Drugs Approved for Treating Breast Cancers


Monoclonal Antibodies


Tyrosine Kinase Inhibitors


The Addressable Market

 

Drugs in Development


Leading Breast Cancer Supplier Assessments